Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures

Am J Gastroenterol. 2009 Dec;104(12):2903-17. doi: 10.1038/ajg.2009.667. Epub 2009 Nov 24.

Abstract

The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects
  • Animals
  • Clinical Trials as Topic
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / therapy
  • Drug Interactions
  • Drug Therapy, Combination
  • Endoscopy, Gastrointestinal* / adverse effects
  • Graft Occlusion, Vascular / etiology
  • Graft Occlusion, Vascular / prevention & control
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control
  • Humans
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Risk Management
  • Stents / adverse effects
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods*

Substances

  • Platelet Aggregation Inhibitors